All In Biotech

Drug Trial Radar · NCT06859788

SPI-1005 for the Treatment of Meniere's Disease (Open Label)

Open-Label Study of SPI-1005 for the Treatment of Meniere's Disease

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 29, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Mar 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.

Conditions

  • Meniere's Disease
  • Ménière's Disease

Interventions

  • EbselenDrug

    Glutathione peroxidase mimetic

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: 180 and 360 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • The House Institute

    Los Angeles, California

  • ENT and Allergy Associates of Florida

    Boynton Beach, Florida

  • ENT and Allergy Associates of Florida

    Delray Beach, Florida

  • Northwell Health

    New Hyde Park, New York

  • ENT and Allergy Associates, LLP

    New York, New York

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • University of Texas Southwestern

    Dallas, Texas

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.